Gene therapy to stimulate angiogenesis to treat diffuse coronary artery disease

Area of Science:

• Cardiovascular Medicine
• Molecular Biology
• Regenerative Medicine

Background:

• Diffuse coronary artery disease (CAD) currently lacks effective therapeutic options.
• Gene therapy using angiogenic mediators has been explored for two decades to revascularize ischemic myocardium.
• Challenges include delivery route, dosing, animal models, treatment duration, and efficacy assessment.

Purpose of the Study:

• To review angiogenesis-based therapeutic approaches for diffuse CAD.
• To summarize key study results in cardiac gene therapy for CAD.
• To provide recommendations for product design and evaluation.

Main Methods:

• Review of preclinical research on angiogenic mediators (e.g., VEGF, FGF, HGF) delivered via DNA plasmids or adenovirus vectors.
• Analysis of experimental models assessing safety and efficacy of gene therapy for myocardial ischemia.
• Summary of clinical studies on cardiac gene therapy with angiogenic factors.

Main Results:

• Preclinical studies demonstrate safety and efficacy of gene therapy for inducing angiogenesis in ischemic hearts.
• Clinical studies provide substantial evidence for the efficacy of angiogenic factors in CAD.
• Definitive clinical studies have not yet resulted in commercial approval.

Conclusions:

• Gene therapy to induce angiogenesis is a viable therapeutic strategy for diffuse CAD.
• Further refinement in product design and evaluation is recommended for successful clinical translation.
• Continued research is essential to overcome challenges and achieve commercial approval for cardiac gene therapy in CAD.